Items where contributor is "Gumpp, Christin"

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2022 | 2020


Radohery, G. F. R. and Walz, A. and Gumpp, C. and Cherkaoui-Rbati, M. H. and Gobeau, N. and Gower, J. and Davenport, M. P. and Rottmann, M. and McCarthy, J. S. and Möhrle, J. J. and Rebelo, M. and Demarta-Gatsi, C. and Khoury, D. S.. (2022) Parasite viability as a measure of in vivo drug activity in preclinical and early clinical antimalarial drug assessment. Antimicrob Agents Chemother, 66 (7). e0011422.

Wicha, S. G. and Walz, A. and Cherkaoui-Rbati, M. H. and Bundgaard, N. and Kuritz, K. and Gumpp, C. and Gobeau, N. and Möhrle, J. and Rottmann, M. and Demarta-Gatsi, C.. (2022) New in vitro interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations. Antimicrob Agents Chemother, 66 (11). e0055622.


Rottmann, Matthias and Jonat, Brian and Gumpp, Christin and Dhingra, Satish K. and Giddins, Marla J. and Yin, Xiaoyan and Badolo, Lassina and Greco, Beatrice and Fidock, David A. and Oeuvray, Claude and Spangenberg, Thomas. (2020) Preclinical antimalarial combination studies: the case of M5717, a P. falciparum elongation factor 2 inhibitor and pyronaridine, a hemozoin formation inhibitor. Antimicrobial agents and chemotherapy, 64 (4). e02181-19.